fda deadline tirzepatide says the weight-loss drug shortage is over Mounjaro will remain off shortage

Experience the remarkable difference Varithena and our other treatments can make

This article explores how GLP-1 medications affect metabolism, who may benefit from treatment, and important safety considerations for UK patients

Only about 20% of employers with 200 or more workers currently cover weight-loss drugs, leaving roughly half of commercially insured patients unable to start or stay on therapy

For most people, it is not truly addictive, but it can become a habit that feels hard to break

These might include rapid sequence induction or point-of-care gastric ultrasound to assess gastric contents and minimise aspiration risk